1. Home
  2. MBBC vs TCRX Comparison

MBBC vs TCRX Comparison

Compare MBBC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marathon Bancorp Inc.

MBBC

Marathon Bancorp Inc.

N/A

Current Price

$15.10

Market Cap

44.1M

Sector

Finance

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$0.24

Market Cap

49.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBBC
TCRX
Founded
1902
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.1M
49.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MBBC
TCRX
Price
$15.10
$0.24
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
3.8K
★ 761.4K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3200.00
12.28
EPS
★ 0.66
N/A
Revenue
N/A
★ $10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.88
★ N/A
Revenue Growth
N/A
★ 266.65
52 Week Low
$10.53
$0.22
52 Week High
$15.79
$2.57

Technical Indicators

Market Signals
Indicator
MBBC
TCRX
Relative Strength Index (RSI) 50.41 24.14
Support Level $14.58 N/A
Resistance Level $15.41 $0.37
Average True Range (ATR) 0.15 0.03
MACD -0.01 0.01
Stochastic Oscillator 63.46 12.62

Price Performance

Historical Comparison
MBBC
TCRX

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: